Article
PTAB Institutes Mylan's Two EYLEA (Aflibercept) IPRs
As we previously reported, Mylan recently filed three IPR petitions challenging claims of Regeneron patents directed to treating angiogenic eye disorders with aflibercept...
Goodwin Procter LLP
